The FDA gives an orphan drug designation to drug candidates that treat a disease that affects less than 200,000 persons in the United States.
The designation is designed to give financial incentives to drugmakers so that drugs for rare diseases will be developed. Those include:
- A 50% tax credit on clinical trial costs
- A break from paying Prescription Drug User Fee Act fees
- The all-important seven years of exclusive sales
Related Fool Articles
Recent Mentions on Fool.com
- 3 Biotech Stocks That Have Been Unfairly Beaten Down
- 3 Reasons ISIS Pharmaceuticals Is a Buy
- 3 Speculative Growth Stocks That Might Be Worth the Risk
- Hillary Clinton's $40 Billion Tweet Breaks Biotech Stocks -- Which 3 Got Hit Hardest?
- Is Dyax Corp. Stock Worth Buying?
- Could These 2 Biopharmas Be the Real Apples of Gilead Sciences' Eye?